A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma  Madeliene Parrott, Simon Rule, Michael Kelleher, Jayne Wilson  Clinical Lymphoma, Myeloma and Leukemia  Volume 18, Issue 1, Pages 13-25.e6 (January 2018) DOI: 10.1016/j.clml.2017.10.004 Copyright © 2017 The Authors Terms and Conditions

Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Diagram Clinical Lymphoma, Myeloma and Leukemia 2018 18, 13-25.e6DOI: (10.1016/j.clml.2017.10.004) Copyright © 2017 The Authors Terms and Conditions

Figure 2 Risk of Bias Summary. ∗Assessment of Blinding of Participants and Personnel Was Not Applicable Because All Trials Were Open Label. The Trials Were Listed as Having an Unclear Risk of Bias Owing to the Restrictions of Choice Within the Bias Tool. Green Indicates a Low Risk of Bias; Yellow, an Unclear Risk of Bias; and Red, a High Risk of Bias Clinical Lymphoma, Myeloma and Leukemia 2018 18, 13-25.e6DOI: (10.1016/j.clml.2017.10.004) Copyright © 2017 The Authors Terms and Conditions

Figure 3 Grade ≥ 3 Hematologic Toxicities Abbreviations: B-R = bendamustine, rituximab; CHOP = cyclophosphamide, doxorubicin, vincristine, prednisolone; FCM = fludarabine, cyclophosphamide, mitoxantrone; F-R = fludarabine, rituximab; G3+ = grade ≥ 3; HD = high dose; Ibrut = ibrutinib; IC = investigator's choice; Lenalid = lenalidomide; maint, maintenance; R-CHOP = rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-FCM = rituximab, fludarabine, cyclophosphamide, mitoxantrone; ritux = rituximab; Tems = temsirolimus. Clinical Lymphoma, Myeloma and Leukemia 2018 18, 13-25.e6DOI: (10.1016/j.clml.2017.10.004) Copyright © 2017 The Authors Terms and Conditions